

**EXPORT LICENSE**

NRC FORM 250



**United States of America**  
 Nuclear Regulatory Commission  
 Washington, D.C. 20555

**NRC LICENSE NO.:** XMAT449/01

Page 1 of 9

**NRC DOCKET NO.:** 11006350

**LICENSE EXPIRES:** December 6, 2021

**Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations herefore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein.**

<p align="center"><b>LICENSEE</b></p> <p>Cambridge Isotope Laboratories, Inc.                  50 Frontage Road                  Andover, MA 01810</p> <p>Attn: Rebecca Dabkowski</p>	<p align="center"><b>ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)</b></p> <p align="center">See following page(s)</p>
<p align="center"><b>INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)</b></p> <p align="center">See following page(s)</p>	<p align="center"><b>OTHER U.S. PARTY(IES) TO EXPORT</b></p> <p align="center">See following page(s)</p>

<b>APPLICANT'S REFERENCE:</b> XMAT449	<b>ULTIMATE DESTINATION:</b> United Kingdom
---------------------------------------	---

<p align="center"><b>QUANTITY(IES)</b></p>	<p align="center"><b>DESCRIPTION OF MATERIAL(S) OR FACILITY(IES)</b></p> <p>This license is amended to: 1) updated the list of the "Ultimate Foreign Consignee(s) in Foreign Country (ies)"; 2) revise the date of expiration from May 31, 2024 to December 06, 2021; and 3) add addresses to Other U.S. Parties to Export.</p> <p>The licensee is authorized to export a cumulative total of 10,000 kilograms of deuterium, in the form of deuterium oxide, deuterium gas, and other compounds. The cumulative total starts from the issuance of the original export license XMAT449.</p>
--	--

<p><b>Neither this license nor any right under this license shall be assigned or otherwise transferred in violation of the provisions of the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974.</b></p> <p><b>This license is subject to the right of recapture or control by Section 108 of the Atomic Energy Act of 1954, as amended, and to all the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of the NRC.</b></p>	<p align="center"><b>THIS LICENSE IS INVALID UNLESS SIGNED BELOW BY AUTHORIZED NRC REPRESENTATIVE</b></p> <p><b>SIGNATURE:</b> <u>David Skeen</u>  <small>Digitally signed by David Skeen                  Date: 2021.11.10 10:15:15 -05'00'</small></p> <p><b>NAME AND TITLE:</b> <u>David L. Skeen, Deputy Director                  Office of International Programs</u></p> <p><b>DATE OF ISSUANCE:</b> <u>November 10, 2021</u></p>
--	--

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

1. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
2. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
3. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
4. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
5. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
6. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
7. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
8. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

9. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
10. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
11. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
12. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
13. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
14. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
15. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
16. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

17. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

18. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

19. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

20. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

21. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

22. [REDACTED]  
United Kinadom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

23. [REDACTED]  
United Kinadom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

24. [REDACTED]  
United Kinadom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

25. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

26. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

27. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

28. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

29. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

30. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

31. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

32. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

33. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

34. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

35. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

36. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

37. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

38. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

39. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

40. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

41. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
42. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
43. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
44. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
45. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
46. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
47. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
48. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

49. [REDACTED]  
United Kingdom  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

1. [REDACTED]  
United Kingdom  
(for distribution to ultimate consignees)

2. [REDACTED]  
United Kingdom  
(for distribution to ultimate consignees)

3. [REDACTED]  
United Kingdom  
(for distribution to ultimate consignees)

4. [REDACTED]  
United Kingdom  
(for distribution to ultimate consignees)

5. [REDACTED]  
United Kingdom  
(for distribution to ultimate consignees)

6. [REDACTED]  
United Kingdom  
(for distribution to ultimate consignees)



**OTHER U.S. PARTY(IES) TO EXPORT:**

1. Cambridge Isotope Laboratories, Inc.  
6 Highwood Drive  
Tewksbury, MA 01876  
(supplier)
  
2. Cambridge Isotope Separations  
1689 Burnett Drive  
Xenia, OH 45385  
(supplier)